title: [Current state of research on multiple sclerosis].
abstract: Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) autoimmune. It belongs to a group of demyelinating disease, which is an irreversible consequence of disability. Epidemiological data indicate that occurs in nearly 2.5 million people around the world. Despite much research is still little known about the disease pathomechanism. Do not we also have so far fully effective the treatment. Available immunomodulatory drugs offer new opportunities defer progression for years. Both fingolimod and natalizumab are more effective in the treatment of MS than the widely used IFN-beta and glatiramer acetate (GA). However, new drugs pose a greater risk of side effects than first-generation drugs. The rapid development of research offers the prospect of a better understanding of the pathogenesis of the disease and to develop more effective treatments.
authors.forename: Natalia
authors.initials: N
authors.lastname: Lubina-Dabrowska
authors.forename: Adam
authors.initials: A
authors.lastname: Stepień
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Chalimoniuk
mesh_terms: D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000627:therapeutic use
chemical_list: D007155:Immunologic Factors; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta